Company Information

  

Address: 8201 E. RIVERSIDE DRIVE
BUILDING 4, SUITE 100 
City: AUSTIN 
State: TX 
Zip Code: 78744 
Telephone: 512-386-2930 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

XBiotech Inc. ("XBiotech" or the "Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human(TM) monoclonal antibodies for treating a variety of diseases. True Human(TM) monoclonal antibodies are those which occur naturally in human beings--as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human(TM) pipeline and manufacturing system. The majority of our efforts to date have been concentrated on developing our lead product candidate, MABp1 (also known as Xilonix(TM), CA-18C3, CV-18C3, RA-18C3, and T2-18C3), a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1 a).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-0.74NAN/E
12/2017-0.95NAN/E
09/2017-1.23NAN/E
06/2017-1.46NAN/E
03/2017-1.63NAN/E
12/2016-1.63NAN/E
09/2016-1.50NAN/E
06/2016-1.46NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.04
Net Inc/Total Assets-0.53Total Liab/Inv Cap0.05
Net Inc/Inv Cap-0.55Total Liab/Comm Equity0.01
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio11.94
Inventory TurnoverNACurrent Ratio11.94
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.16 1.60 1.66 2.29
Operating Income -4.15 -7.51 -6.59 -9.69
Interest Exp NA NA NA NA
Pretax Income -4.07 -7.25 -6.21 -9.13
Other Income 0.08 0.26 0.39 0.56
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.07 -7.25 -6.21 -9.13

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 28.42 31.77 38.98 45.95
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 29.75 33.33 40.29 47.30
Net Property, Plant & Equipment 29.11 29.64 30.38 30.54
Total Assets 58.86 62.97 70.67 77.84
Liabilities        
Accounts Payable 2.43 2.79 3.50 4.66
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 2.43 2.79 3.50 4.66
Long-Term Debt NA NA NA NA
Total Liabilities 2.45 2.81 3.52 4.69
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 277.80 277.49 277.08 276.59
Retained Earnings -220.63 -216.56 -209.31 -203.11
Treasury Stock NA NA NA NA
Total Stockholders' Equity 56.41 60.16 67.15 73.16
Total Liabilities and Stockholders' Equity 58.86 62.97 70.67 77.84

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -3.53 -6.81 -6.47 -8.47
Net Cash Provided by Investing Activities -0.03 -0.25 -0.26 -0.28
Net Cash Provided by Financing Activities 0.20 0.00 0.05 0.56

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-9.93--
12/20140.00-21.72--
12/20150.00-37.48-1.22
12/20160.00-52.76-1.63
12/20170.00-33.15-0.95
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18463,1538.88




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.